Current clinical status for ischemic heart disease

Currently 172 million patients are suffer from ischemic heart disease in Japan. Ischemic heart disease is the second largest cause of death in Japan. Over 50,000 patients lose their lives to this affliction annually.

Incidence of ischemic heart disease is increasing annually: 190,000 people present with this disease per year.

No magic wand to cure ischemic heart disease at the moment. Effective new therapies are sought and CellSeed has responded to this need with a novel solution.

What is the living regenerative cardiac patch?

To improve clinical options and outcomes, CellSeed has innovated a new therapy, a "regenerative cardiac patch".

CellSeed's regenerative cardiac patch requires a patient's own myoblast cells, growing these cells in culture on our specially treated cell culture dish UpCell® creating a viable, beating myocytes cell sheet. This cultured cell-sheet is harvested intact using our technology and stacked to the other cell-sheets to achieve multiple-layered cell-sheet, the "cardiac patch". The "cardiac patch" is a living, spontaneously pulsatile, contractile cardiomyocyte replacement. Transplanted to damaged parts of the patient's heart, these pulsatile sheets synchronize with the beating heart to provide added cardiac contractile capability.

Applications

Ischemic heart disease animal models and potentially human heart disease.

What are the advantages of CellSeed's regenerative living cardiac patch?

This new "regenerative cardiac patch" therapy as well as individually tailored cell therapy represent alternative opportunities to study and treat ischemic heart disease.

Currently, graft survival rates for cell therapy are low with questionable efficiency.

CellSeed's living "cardiac patch" dramatically improves cell survival and function. Direct application of the "cardiac patch" to the damaged myocardium requires no suture. Graft survival rate for the "cardiac patch" is close as 100% since it is a "sheet". Rejection is not an immunological concern since an autograft is created.

Where is this surgery with CellSeed's living cardiac patch available?

The approach is still under pre-clinical testing in animal models. Research is a joint collaboration with Tokyo Women's Medical University and Osaka University. We are attending every possible effort to provide this innovative solution to patients as soon as it is proven safe and efficacious.